A study to investigate safety, tolerability, pharmacokinetics, and pharmacodynamics of AZD1705 in participants with dyslipidemia

Trial Identifier: D7650C00001
Sponsor: AstraZeneca
Collaborator:
Parexel
NCTID:: NCT06238466
Start Date: January 2024
Primary Completion Date: September 2025
Study Completion Date: September 2025

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
US, CA Glendale, CA, US, 91206
US, FL Jacksonville, FL, US, 32216
US, KS Overland Park, KS, US, 66212
US, MD Baltimore, MD, US, 21225
US, TX San Antonio, TX, US, 78229